European Urology

European Urology, abbreviated as Eur Urol (ISSN: 0302-2838), is a premier peer-reviewed medical journal dedicated to the field of urology. Published by Elsevier on behalf of the European Association of Urology, the journal serves as the leading international forum for the dissemination of cutting-edge clinical and translational research. Its scope encompasses the full spectrum of urological disorders, including but not limited to prostate cancer, bladder cancer, kidney cancer, testicular cancer, benign prostatic hyperplasia, urinary tract infections, incontinence, erectile dysfunction, and renal transplantation. The journal publishes a variety of article types, including original research articles, comprehensive reviews, state-of-the-art updates, editorials, and surgical technique innovations, with a strong emphasis on high-impact studies that directly influence clinical practice and patient outcomes. Target audiences include urologists, oncologists, nephrologists, radiologists, pathologists, and basic science researchers focused on urogenital diseases. As of 2026, European Urology holds an exceptional Journal Impact Factor of 29.100, placing it in the JCR Quartile 1 (Q1) and consistently ranking it among the top journals in urology and nephrology. While the journal primarily operates on a subscription-based model, it offers an open access option for authors, ensuring broad dissemination of pivotal findings. Its rigorous editorial standards, rapid review process, and global readership solidify its standing as the highest-impact journal in the urology specialty, making it an essential resource for clinicians and scientists seeking the most authoritative and influential evidence in the field.